gliadel
mgi pharma gmbh - carmustina - carmustina
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustina - hodgkin disease; lymphoma, non-hodgkin - agenti antineoplastici - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
bicnu
tillomed italia srl - carmustina - carmustina
carmustina waymade
waymade bv - carmustina - carmustina
carmustina accordpharma
accord healthcare, s.l.u. - carmustina - carmustina
carmustina aurobindo
eugia pharma (malta) limited - carmustina - carmustina
bicnu 100 mg polvere e solvente per soluzione per infusione
ideogen ag - carmustinum - polvere e solvente per soluzione per infusione - preparazione a secco: carmustinum 100 mg, per il vetro. il rilascio di: ethanolum anhydricum 3 ml, per il vetro. - salvataggio di terapia in caso di recidiva di grado iii e iv gliomi, il linfoma di hodgkin e non-hodgkin linfomi come parte di un myeloablativen konditionierungsschemas - synthetika
carmustina accord
accord healthcare, s.l.u. - carmustina - carmustina